 -- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight 75 Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up -- -- All Patients with Pain at Baseline Reported Zero Pain by Week 3 -- -- KPI-012 was Well-Tolerated with No Significant Safety Issues Observed -- -- On Track to Submit Investigational New Drug Application IND and Initiate Phase 23 Trial in 4Q 2022 -- ARLINGTON, Mass., May 01, 2022 GLOBE NEWSWIRE -- Kala Pharmaceuticals, Inc. NASDAQ:KALA, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven by impaired healing. As previously disclosed, treatment with KPI-012 was well tolerated and resulted in significant improvements in patients with various persistent corneal epithelial defect PCED etiologies, with complete healing of the PCED in six of eight evaluable patients. The data will be presented on Tuesday, May 3 in a poster session at the 2022 Association for Research in Vision and Ophthalmology ARVO Annual Meeting. 